Final Results of the Sakk 16/00 Trial: a Randomized Phase III Trial Comparing Neoadjuvant Chemoradiation to Chemotherapy Alone in Stage Iiia/N2 Non-Small Cell Lung Cancer (Nsclc)
Miklos Pless(Ontario Institute for Cancer Research), Sönke Peters, Alexandros Xyrafas(Swiss Group For Clinical Cancer Research), Adrian F. Ochsenbein(University of Bern), Martin Früh(University of Bern), Sandra Thierstein(Swiss Group For Clinical Cancer Research), Richard Cathomas(Kantonsspital Graubünden), Roger Stupp(Northwestern University), DC Betticher, Alfred Zippelius(University of Basel), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Walter Weder(Krankenhaus Bethanien), Christoph Mamot(Kantonsspital Aarau), Urs R. Meier(Kantonsspital Winterthur), A Roth(Helios Klinikum Emil von Behring), H. Ris(Centre Hospitalier Universitaire Vaudois), René‐Olivier Mirimanoff(University of Lausanne), Daniel Rauch(Washington University in St. Louis), Marie-Aline Gérard(Swiss Group For Clinical Cancer Research), Rolf A. Stahel(International Breast Cancer Study Group)
Cited by 13
Related Papers
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k